Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui , former Chief Scientific Advisor of Operation Warp Speed & former Chair of R&D at GlaxoSmithKline and Khurem Farooq, previously CEO of Aiolos, join Board of Directors LONDON Nov. 21, 2024 /PRNewswire/ -- Vicebio Ltd ("Vicebio"), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ongoing VXB-241 bivalent RSV-hMPV Phase 1 (P1) study as well as the appointment of Moncef Slaoui , PhD, and Khurem Farooq to its Board of Directors. Vicebio is progressing into the second stage of its clinical study of VXB-241 and is now enrolling individuals aged 60 years of age and above to evaluate the candidate vaccine's safety in this vulnerable population. Early data from the study are expected by mid-2025. Vicebio anticip
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics to Present at Jefferies London Healthcare ConferenceBusiness Wire
- Meiji Seika Pharma Announces Investment in ARCALIS, Inc.Business Wire
- Arcturus gets FDA clearance for H5N1 avian flu vaccine study [Seeking Alpha]Seeking Alpha
- Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical TrialBusiness Wire
- Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 11/7/24 - Beat
ARCT
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- ARCT's page on the SEC website